International Stem Cell Corp. (OTCQB: ISCO) is a
biotechnology company that works with parthenogenesis to treat diseases of the
eyes, the nervous system, the liver, and more. Currently, ISCO is preparing for
a phase I clinical trial of its proprietary human parthenogenetic stem
cells-derived neural stem cells (ISC-hpNSC®) for the treatment of Parkinson’s
disease (PD), a disease of the nervous system that affects mainly middle-aged
and elderly people. The disease is marked by tremors, muscular rigidity, and
slow movements. The company’s lead product, ISC-hpNSC, works in a different way
than other conventional treatments. The stem cells enable protection of the
remaining, fully-functional neurons of Parkinson’s disease patients. The
testing ISCO has done on mice, rats, and non-human primates has backed its
theory that a one-time transplant of ISC-hpNSC could alleviate current PD
symptoms and prevent the disease from spreading.
Recently, Edison, an international equity research firm,
initiated coverage on International Stem Cell Corp. The report focuses on
ISCO’s parthenogenetic stem cell technology and how this technology has the
potential to treat a variety of diseases. The report also includes an
investment summary, a description of ISCO as a company, an outline of
Parkinson’s disease, insight into ISCO’s cosmeceutical and biomedical business
lines, a valuation, and a financial overview.
With the help of Cryoport, the world’s premier cryogenic
logistics firm, International Stem Cell Corp. is rapidly approaching the start
of its phase I clinical trial for the treatment of Parkinson’s disease. So far,
there have been a number of cell therapy and gene therapy treatments that have
been evaluated to find the cause of Parkinson’s. The studies ISCO has
undertaken on non-human subjects have shown significant results.
According to the initial coverage issued by Edison: “ISCO
presented results of its PD preclinical studies in October 2015 at Neuroscience
2015 in Chicago. The preclinical studies on 18 non-human primates showed that
at 12 months, the transplanted cells had integrated into the dopamine fibers
and dopamine levels post-mortem were significantly higher in the transplanted
group versus the control group.”
As part of its impending clinical study, each patient will
receive a scan at the beginning of the trial and at the six-month and 12-month
lines after the procedure. Although these procedures do come with risks, they
will be performed at the well-known Royal Melbourne Hospital in Australia and,
if successful, could lead to larger phase II trials in 2017/2018.
For more information, visit www.internationalstemcell.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
